Bio-Rad Laboratories Inc (BIO)

Debt-to-equity ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Long-term debt US$ in thousands 1,199,100 1,198,710 1,198,380 1,198,000 1,197,700 1,197,270 1,196,940 1,196,740 10,514 10,600 10,779 10,901 12,258 12,241 12,200 12,205 13,579 437,808 437,680 437,600
Total stockholders’ equity US$ in thousands 8,741,130 8,416,200 8,446,890 9,763,720 9,615,250 8,477,470 8,945,040 10,203,300 13,685,200 15,332,400 11,594,900 10,609,100 9,889,690 8,825,140 7,353,400 6,293,080 5,756,840 5,131,190 5,486,810 4,863,860
Debt-to-equity ratio 0.14 0.14 0.14 0.12 0.12 0.14 0.13 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.08 0.09

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,199,100K ÷ $8,741,130K
= 0.14

The debt-to-equity ratio of Bio-Rad Laboratories Inc. has remained relatively stable over the past eight quarters, ranging between 0.12 and 0.14. This ratio indicates that the company has been maintaining a healthy balance between debt and equity in its capital structure.

A debt-to-equity ratio of 0.14 implies that for every dollar of equity, the company has $0.14 in debt. This suggests that Bio-Rad Laboratories relies more on equity financing rather than debt financing to support its operations and growth. A lower debt-to-equity ratio is generally seen as a positive indicator as it signifies lower financial risk and greater financial stability.

The consistency in the debt-to-equity ratio over the quarters reflects the company's cautious approach towards managing its debt levels. By keeping the ratio relatively low and stable, Bio-Rad Laboratories demonstrates financial prudence and a commitment to maintaining a strong financial position.

Overall, based on the trend of the debt-to-equity ratio over the past two years, Bio-Rad Laboratories Inc. appears to be managing its capital structure effectively and maintaining a balanced mix of debt and equity to support its operations and growth strategy.